Where Tech Meets Bio

Weekly Tech+Bio #83: The FDA Might Test Clinical AI Like It Tests Doctors

ALSO: Can Claude design proteins? Ageing virtual cells, DNA as a programmable building material, and the tech+bio week in brief.

Aug 26 • Andrii Buvailo, PhD and BiopharmaTrend

8

2

Weekly Tech+Bio #82: Industry Vets Grade AI's Progress; Frontier AI Labs Enter CRO Industry; The Rise of In Vivo CAR-T, and More...

Also: IMPORTANT UPDATE ABOUT OUR NEWSLETTER

Aug 18 • Andrii Buvailo, PhD and BiopharmaTrend

6

6

2

July 2026

Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

AlSO: The Numbers Behind China's Biopharma Ascent

Jul 2 • Andrii Buvailo, PhD

38

14

5

June 2026

My Seven Health Tech Observations From HLTH Europe 2026 Event

AI is moving from writing clinical notes to checking them. "Human-in-the-loop" is becoming a product, not a footnote. Nearly everyone is racing to own…

Jun 26 • Andrii Buvailo, PhD

16

1

Is the Future of AI Drug Discovery Hybrid?

Some field notes from the cutting edge of modern bioinformatics (CoFold Summit and Free Energy Workshop, both held recently in Barcelona, Spain). ALSO…

Jun 1 • Andrii Buvailo, PhD

29

2

May 2026

Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed...

May 21 • Andrii Buvailo, PhD and Roman Kasianov

37

6

5

April 2026

From Biohacking to Healthcare: The Growing Pains of the Longevity Industry

Part I: A tour of the therapeutic strategies targeting the hallmarks of aging—from cellular reprogramming to senolytics, mTOR inhibitors, and immune…

Apr 16 • Louise von Stechow and BiopharmaTrend

33

2

7

Weekly Tech+Bio #81: AI Agents at the Cancer Conference

AI-pharma deals track toward a 12x increase in five years, Life Biosciences takes reprogramming to Phase 1, and Jeito closes Europe's largest…

Apr 14 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend

16

2

Weekly Tech+Bio #80: Organoids on Artemis II

Anthropic's $400M AI biotech acqui-hire, CRO stocks reprice, new EMA draft, and pharma's spring acquisition spree

Apr 6 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend

12

4

4

Everyone is Launching AI Agents. What's Being Deployed?

A deep dive on the next cycle of biopharma's AI buildout

Apr 4 • Roman Kasianov and Andrii Buvailo, PhD

22

2

4

March 2026

Weekly Tech+Bio Highlights #79: A Pharma Factory in an Egg

Lilly's $2.75B generative chemistry deal and why AI research might be locked into 'hypernormal' science

Mar 30 • Roman Kasianov and Andrii Buvailo, PhD

9

3

Weekly Tech+Bio Highlights #78: AI Agents Rush In

Roche and Lilly scale up pharma's biggest AI supercomputers, a billion-dollar startup unveils its virtual cell, ex-GSK AI leaders launch startup, and…

Mar 23 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend

15

3